Allogene Therapeutics ALLO Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's restricted cash?
- Allogene Therapeutics (ALLO) reported restricted cash of $10.29M in Q1 2026.
- How has Allogene Therapeutics's restricted cash changed year-over-year?
- Allogene Therapeutics's restricted cash decreased by 0.0% year-over-year, from $10.29M to $10.29M.
- What is the long-term trend for Allogene Therapeutics's restricted cash?
- Over 5 years (2020 to 2025), Allogene Therapeutics's restricted cash has grown at a 1.7% compound annual growth rate (CAGR), from $9.45M to $10.29M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.